Astrazeneca Ab

Astrazene&cacute;a Ab

Ast&racute;azeneca Ab

Tord Bertil Inghardt

Eva-Lotte Lindstedt-Alstermark

Petra Johannesson

Nicholas Tomkinson

Ulrik Jurva

Jan-Erik Nystr&ouml;m

Marcel Linschoten

Jeffrey Paul Stonehouse

Olle Karlsson

Arne Svensson

Erik Michaelsson

Li-Ming Gan

Martin Hans Bohlin

Kjell Andersson

Anita Lundblad

Maria Boije

Anders Johansson

Carl-Gustaf Sigfridsson

Matti Ahlqvist

Lanna Li

Daniel Tor Pettersen

Karol Horvath

Eva-Lotte Lindstedt Alstermark

Johan Gottfries

Jan-Erik Nyström

Jon Paul Janet

Björn Erik Anton Holm

Fabrizio Giordanetto

Gunnel Sund&eacute;n

Stéphanie Marcelle Gueret

Nidhal Selmi

Erik Lars Malmerberg

Jan Åke Lindberg

Jens Peter Brandt

Erik MICHAËLSSON

The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.

Amido heteroaromatic compounds

There are disclosed certain 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one compounds of formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions.

1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase

There is provided a compound of formula (I) wherein R, R, R, Y and Rhave meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Mandelic acid derivatives and their use as thrombin inhibitors

There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein Rrepresents Calkyl substituted by one or more fluoro substituents; Rrepresents Calkyl; and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required.

Salts

The present invention provides compounds of the class of thienopyrimidines, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, type II diabetes, Metabolic syndrome and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and pain related disorders, and to pharmaceutical compositions containing them.

Thienopyrimidine compounds and uses thereof

There is provided pharmaceutically-acceptable acid addition salts of compounds of formula I, whereinRrepresents Calkyl substituted by one or more fluoro substituents;Rrepresents Calkyl; andn represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

There is provided compounds of formula I wherein R, R, Y, R, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Amidino derivatives and their use as thrombin inhibitors

There is provided a compound of formula I wherein R, R, R, Y and Rhave meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

There is provided a compound of formula (1) and pharmaceutically-acceptable derivatives (including prodrugs) thereof. Which compound and derivatives are useful as, or are as useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Thiochromane derivatives and their use as thrombin inhibitors

Growing community of inventors

Mölndal, Sweden

Tord Bertil Inghardt